

Heterogeneity and district-level factors associated with COVID-19 mortality during three epidemic waves in Indonesia: a nationwide ecological study

Authors: Henry Surendra^{1,2,3*}, Danarastri Paramita^{2,3}, Nora N Arista³, Annisa I Putri^{2,4}, Akbar A Siregar^{2,4}, Evelyn Puspaningrum¹, Leni Rosylin², Dida Gardera², Montty Girianna², Iqbal RF Elyazar¹

¹ Oxford University Clinical Research Unit, Jakarta, Indonesia

² Komite Pengendalian COVID-19 dan Pemulihan Ekonomi Nasional, Jakarta, Indonesia

³ United Nations Development Program, Jakarta, Indonesia

⁴ United States Agency of International Development, Jakarta, Indonesia

Corresponding author:

Henry Surendra PhD.

Oxford University Clinical Research Unit

Jalan Diponegoro 69

10430 Jakarta, Indonesia.

Phone: (021) 3910414

Email: henrysurendra.15@gmail.com and hsurendra@eocru.org

Abstract

Introduction Ensuring health equity, especially for vulnerable populations in less developed settings with poor health system is essential for the current and future global health threats. This study examined the heterogeneity of COVID-19 mortality and its association with population health characteristics, health care capacity in responding pandemic, and socio-economic characteristics across 514 districts in Indonesia.

Methods This nationwide ecological study included aggregated COVID-19 cases data from all 514 districts in Indonesia, recorded in the National COVID-19 Task Force database, during the first two years of the epidemic, from 1 March 2020 to 27 February 2022. We calculated incidence and mortality rate by time, sex, and age. We extracted district-level socio-demographics, population health, and health care capacity data from government official sources. We used multivariable linear regression to examine factors associated with higher mortality rate.

Results Of total 5,539,333 reported cases, 148,034 (2.7%) died, and 5,391,299 (97.4%) were recovered. The national mortality rate was 55 per 100,000 population, ranged from 13 per 100,000 population in Papua to 156 per 100,000 population in East Kalimantan province. At district-level, higher mortality rate was associated with higher COVID-19 incidence ($p < 0.0001$), higher proportion of ≥ 60 years old population ($p < 0.0001$), higher prevalence of diabetes mellitus ($p < 0.0001$), lower prevalence of obesity ($p = 0.019$), lower number of doctors per population ($p = 0.001$), higher life expectancy at birth ($p = 0.035$), and lower formal education ($p = 0.021$). There was no association between COVID-19 mortality rate with expenditure, prevalence of hypertension and pneumonia, vaccine coverage for ≥ 60 years old population, number of nurses, midwives, and hospitals per population ($p > 0.05$ each).

Conclusion COVID-19 mortality rate in Indonesia was highly heterogeneous and associated with different prevalence of pre-existing comorbidity, healthcare capacity in responding the pandemic, and socio-economic characteristics. This study revealed the need of health capacity strengthening and better resource allocation to ensure optimal health outcomes for vulnerable population.

What is already known on this topic

- The severity of COVID-19 illness and clinical outcomes can be affected by the concentration of comorbidities in susceptible groups in communities, and through disparities of access to health care for preventive measures or prompt diagnosis and treatment.
- However, evidence on the heterogeneity of COVID-19 impact from low- and middle-income country (LMIC) where differences in age distribution, comorbidities, access to quality health services, and other factors, may greatly influence mortality risk, are limited.

What this study adds

- This study affirmed that COVID-19 disproportionately affected areas with high proportion of elder population, high prevalence of diabetes mellitus, lower doctor to population ratio, higher life expectancy at birth, and lower level of formal education.
- These findings indicate that vulnerability to death associated with COVID-19 in LMIC includes not only elder and comorbid, but also males and communities living in area with lower health care capacity and with lower level of education.

How this study might affect research, practice and/or policy

- These findings may inform decisions on health resource allocation against COVID-19 delivering the greatest possible health dividends by prioritising interventions, including even distribution of essential health care need such as doctors, and a tailored risk communication and community engagement for the most vulnerable communities in LMIC, especially with decentralised health systems like in Indonesia.

Background

Globally, coronavirus disease 2019 (COVID-19) pandemic has caused millions of deaths [1], public health systems collapse [2], and socio-economic disruptions [3,4]. As of 17 June 2022, there have been 535,863,950 total confirmed cases and 6,314,972 deaths reported to the World Health Organization (WHO) [1]. It was reported that employment loss rates have been high since the beginning of the pandemic, and significantly higher among women than men (26% vs 20% in September 2021), with a steadily decreasing trend worldwide [3]. Income loss was reported at 58.4%, with higher rates seen in less developed settings such as Sub-Saharan Africa, Southeast Asia, east Asia, and Oceania [3]. As per 15 June 2022, 11,902,271,619 vaccine doses have been administered [1], yet the pandemic continues to affect the global population, especially the most vulnerable communities.

Ensuring health equity, especially for vulnerable populations in less developed settings with poor health systems is essential for the current COVID-19 pandemic and future global health threats [5-10]. At community-level, it is known that the severity of illness and clinical outcomes can be affected by the concentration of comorbidities in susceptible groups in communities [11-14], and through disparities in access to health care for preventive measures or prompt diagnosis and treatment [14,15]. Recent findings in US, Chile and Brazil suggested that COVID-19 poor outcome was concentrated in groups with higher socio-demographics and health system vulnerability [14, 16-20]. However, the heterogeneity of COVID-19 impacts from low- and middle-income countries (LMIC) where differences in age distribution, comorbidities, access to quality health services, and other factors, may significantly influence mortality risk, are limited.

Indonesia has suffered the highest number of COVID-19 confirmed cases and deaths in Southeast Asia, second only to India in all of Asia [21], at 6,068,075 cases and 156,687 deaths (2.6% case fatality rate (CFR)) up to 19 June 2022 [22]. The first SARS-CoV-2 epidemic wave occurred from 2 March 2020 to 30 April 2021, and a more intense second wave dominated by Delta variant peaked in July 2021 [23], followed by the third wave peaked in February 2022 [22]. The majority of cases and deaths in Indonesia were reported in Java Island, a more developed setting populated by 152 million individuals (56% of the total Indonesia's population). Recent studies from Indonesia's capital city of Jakarta suggested that COVID-19 disproportionately affected individuals with older age and pre-existing chronic comorbidities, as well as those areas with lower vaccine coverage, and higher poverty and population density [24,25]. However, data on the impact of COVID-19 across 514 districts of Indonesia that have different pre-existing

burdens of major infectious diseases such as malaria, tuberculosis, HIV and other tropical infections [26], as well as non-communicable diseases like cardiovascular diseases, cancers, chronic pulmonary diseases, diabetes, and others [27], are scarce.

Indonesia is the fourth most populous country (population 270 million) and the LMIC featuring great geographic, cultural and socio-economic diversity across the archipelago. The 2020 human development index (HDI) ranged from 0.32 in Nduga District, Papua to 0.87 in Yogyakarta city, Yogyakarta [28]. In addition, substantial proportions of the Indonesian population face barriers in accessing quality health care services due to under-resourced and fragile health systems [26]. A heavily decentralised health systems [30] has resulted in distinct public health capacity across 514 districts of Indonesia. For example, the 2018 Public Health Development Index (PHDI) ranges from 35% in Paniai district, Papua province to 75% in Gianyar district, Bali province [31]. That heterogeneity and the large number of COVID-19 cases and deaths provides insights directly relevant to the national public health response to the COVID-19 crisis, and other LMIC settings. In this study, we assessed the COVID-19 heterogeneity, district-level socio-economics, population health-related conditions, and health care capacity among 514 districts of Indonesia and how those factors were associated with COVID-19 mortality rate during the first 24 months of the epidemic in Indonesia (March 2020 through February 2022).

Methods

Study design and participants

This was a nationwide ecological study to assess COVID-19 burden, heterogeneity, and factors associated with mortality rate in all 514 districts in Indonesia. The study analysed aggregated data of individuals diagnosed with COVID-19 based on either rapid antigen diagnostic test (Ag RDT) or polymerase chain reaction (PCR) recorded by the National COVID-19 Task Force from 1 March 2020 to 27 February 2022. In accordance with Indonesia's national COVID-19 guideline, individuals are categorized as COVID-19 confirmed cases if tested positive by Ag RDT or PCR.

The main outcome variable in this study was district-level COVID-19 mortality rate per 100,000 population. The determinants assessed were gender, proportion of ≥ 60 years old individuals, prevalence of hypertension, prevalence of diabetes mellitus, prevalence of obesity, prevalence of pneumonia, COVID-19 vaccine coverage for ≥ 60 years old population, number of doctors, nurses, midwives, and hospitals per 10,000 population, expenditure, life expectancy at birth, and length of formal education.

Patient and public involvement

This study did not include patients and public in the design, or conduct, or reporting, or dissemination plans. This study was a secondary analysis of aggregated routine surveillance data conducted under a formal collaboration between the National COVID-19 Task Force (Komite Pengendalian COVID-19 dan Pemulihan Ekonomi Nasional) and United Nation Development Program, Indonesia.

Data collection

The aggregated data of weekly number of COVID-19 cases, incidence rate per 100,000 population, number of COVID-19 deaths among confirmed cases, mortality rate per 100,000 population, by district, sex, and age group from 1 March 2020 to 27 February 2022 were collected from the government official COVID-19 database managed by the National COVID-19 Task Force.

District-level data were collected from various government sources. Data on the number of populations were collected from Statistics Bureau Database available in each province. Data on the number of doctors, nurses, midwives, and hospitals per October 2021 were collected from the Indonesia Ministry of Health records. Data on prevalence of hypertension, diabetes mellitus, obesity, and pneumonia were collected from the National Public Health Development Index 2018 Report [31]. Data on the COVID-19 two-dose vaccine coverage for ≥ 60 years old population by district per 27 February 2022 were collected from the National COVID-19 Vaccination Database. Data on expenditure, life expectancy at birth, and length of formal education were collected from the Human Development Index 2020 Report [28].

Statistical analysis

Incidence and mortality rate per 100,000 population was calculated by time (weekly), sex, and province. Male to female incidence and mortality rate ratio (RR) was calculated to compare risk between males and females, and by province. Maps showing spatial distribution of male to female incidence and mortality rate ratio were generated using QGIS 3.20 software.

District-level incidence and mortality rate per 100,000 population, proportion of ≥ 60 years old population, prevalence of hypertension (%), prevalence of diabetes mellitus (%), prevalence of obesity (%), prevalence of pneumonia (%), COVID-19 vaccine coverage for ≥ 60 years old population (%), number of doctors, nurses, midwives, and hospitals per 100,000 population, expenditure (millions IDR), life expectancy at birth (years), and length of formal education (years)

were calculated then categorised into quartiles. Descriptive statistics included proportions and the chi-squared test to compare district-level characteristics between different quartiles. Spearman's correlation tests were done to assess correlation between each district-level variable. We used bivariable and multivariable linear regression models to determine factors associated with higher mortality rate at district level, expressed as beta, with 95% confidence intervals. All independent variables with p-value <0.10 in bivariable analysis were included in the multivariable models. Final model selection was informed by likelihood ratio tests. We set statistical significance at 0.05, and all tests were two-sided. All analyses were done in Stata/IC 15.1 (StataCorp, College Station, TX, USA). This study is reported as per Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [31].

Ethics

This study was a secondary analysis of aggregated routine surveillance data collected by COVID-19 control program, with district as the analysis unit. Use of the data, which was aggregated, and at the population level is permitted by the Indonesian Ministry of Health under Regulation Number 45 (2014), Article 3, paragraphs 1 and 2. There was no ethical approval sought for this study.

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all data and the final responsibility to submit for publication.

Results

Cumulative COVID-19 incidence and mortality rate

Table 1 presents the reported cumulative COVID-19 incidence and mortality rate in Indonesia between 1 March 2020 and 27 February 2022. A total of 5,539,333 COVID-19 cases were recorded on the Indonesia National COVID-19 Database. Of those, 148,034 (2.7%) were deceased, and 5,391,299 (97.4%) were recovered. The overall incidence and mortality rates were 2,050 and 55 per 100,000 population, respectively. The incidence and mortality rate varied widely by province. The highest incidence rate was reported in DKI Jakarta (10,764 cases per 100,000 population), and the lowest was reported in West Nusa Tenggara (667 cases per 100,000 population). The highest mortality rate was reported in East Kalimantan (156 per 100,000 population), while the lowest was reported in Papua (13 per 100,000 population).

Table 1. Cumulative COVID-19 incidence and mortality rate between March 2020 and February 2022 in Indonesia, stratified by province

Region/Province	Total cases	Incidence per 100,000 population	Total deaths	Mortality per 100,000 population
Overall	5,539,333	2,050.06	148,034	54.79
Sumatera				
Aceh	40,302	768.06	2,087	39.77
North Sumatera	139,683	939.05	2,954	19.86
West Sumatera	98,913	1,792.15	2,191	39.77
Riau	141,166	2,324.06	4,170	68.65
Jambi	33,924	971.10	798	22.84
South Sumatera	76,343	929.02	3,162	38.48
Bengkulu	26,951	1,347.86	482	24.11
Lampung	64,718	711.53	3,952	43.45
Bangka Belitung Islands	58,493	4,293.34	1,487	107.77
Riau Islands	63,683	3,300.66	1,772	91.84
Java				
DKI Jakarta	1,167,506	10,764.25	14,585	134.47
West Java	999,997	2,214.28	15,048	33.32
Central Java	573,628	1,577.46	30,976	85.18
Yogyakarta	190,336	5,241.95	5,370	147.89
East Java	531,169	1,312.21	30,296	74.84
Banten	265,041	2,471.85	2,829	26.38
Bali and Nusa Tenggara				
Bali	152,466	3,616.22	4,390	104.12
West Nusa Tenggara	35,133	666.63	863	16.37
East Nusa Tenggara	73,736	1,362.62	1,365	25.22
Kalimantan				
West Kalimantan	52,597	969.92	1,078	19.88
Central Kalimantan	52,114	2,027.55	1,454	56.57
South Kalimantan	81,842	2,034.33	2,462	61.20
East Kalimantan	187,834	5,287.84	5,525	155.54
North Kalimantan	38,752	5,976.49	813	125.38
Sulawesi				
North Sulawesi	48,412	1,832.48	1,103	41.75
Central Sulawesi	52,470	1,775.29	1,621	54.85
South Sulawesi	134,225	1,423.85	2,327	24.68
Southeast Sulawesi	24,529	930.73	545	20.68
Gorontalo	12,854	1,088.72	462	39.13
West Sulawesi	13,723	879.69	357	22.88
Maluku and Papua				
Maluku	18,382	995.18	279	15.10
North Maluku	13,490	1,031.50	308	23.55
West Papua	29,129	2,553.61	362	31.73
Papua	45,792	1,055.03	561	12.93

Heterogeneity of COVID-19 incidence and mortality rate at province-level




Figure 1. COVID-19 incidence and mortality over the first three epidemic waves in Indonesia between March 2020 to February 2022.

Figure 1 shows the weekly incidence and mortality at the national and province-level. The data suggest that Indonesia had experienced three pandemic waves with the highest mortality recorded in week 73rd (12 to 18 July 2021) where cases were predominantly infected by Delta variant (Figure 1). The province-level data show that DKI Jakarta had consistently experienced the highest incidence rate over time (Figure 2A). Overall, the mortality rate increased over time, with the highest rate seen in East Kalimantan, followed by Yogyakarta, DKI Jakarta, and North Kalimantan (Figure 2B).

The mortality rate was higher for males than females across 34 provinces in Indonesia (Table 2), with the highest male to female mortality rate ratio (RR) seen in East Nusa Tenggara (RR 3.00), followed by Yogyakarta (RR 2.61), Southeast Sulawesi (RR 2.52), Banten (RR 2.51), and West Papua (RR 2.50). The lowest male to female mortality was reported in Aceh province (RR 1.15). The incidence rate was also higher for males than females in the majority of provinces (94.12%), except for in Aceh and Bali (RR 0.92 and 0.99, respectively) (Supplementary Table 1). The highest male to female mortality rate ratio was seen in East Kalimantan (RR 2.42), followed by North Kalimantan (RR 2.17), Riau islands, Papua, and West Papua (RR 2.12 each).

Table 2. Overall COVID-19 mortality rate between March 2020 and February 2022 in Indonesia by sex and province

Province	Male			Number of Deaths	Female		Male-female mortality rate ratio
	Number of Deaths	Number of Population	Mortality per 100,000 population		Number of Population	Mortality per 100,000 population	
Aceh	1114	2,691,800	41.38	973	2,696,300	36.09	1.15
Bali	2664	2,221,400	119.92	1719	2,193,100	78.38	1.53
Banten	1570	6,557,900	23.94	1232	12,895,300	9.55	2.51
Bengkulu	236	1,015,200	23.25	237	1,994,300	11.88	1.96
Yogyakarta	3020	1,935,400	156.04	2346	3,919,200	59.86	2.61
Jakarta	7734	5,267,800	146.81	6727	10,576,400	63.60	2.31
Gorontalo	245	593,500	41.28	217	1,186,300	18.29	2.26
Jambi	401	1,831,300	21.90	377	3,604,200	10.46	2.09
West Java	7666	25,111,200	30.53	7357	49,565,200	14.84	2.06
Central Java	15,750	17,237,300	91.37	14,192	34,738,200	40.85	2.24
East Java	14,962	19,722,200	75.86	14,907	39,955,900	37.31	2.03
West Kalimantan	593	2,591,400	22.88	481	5,104,900	9.42	2.43
South Kalimantan	1355	2,156,700	62.83	1096	4,268,600	25.68	2.45
Central Kalimantan	791	1,394,900	56.71	659	2,686,300	24.53	2.31
East Kalimantan	2946	1,902,900	154.82	2566	3,664,700	70.02	2.21
North Kalimantan	405	374,100	108.26	402	708,400	56.75	1.91
Bangka Belitung Islands	706	756,900	93.28	780	1,469,800	53.07	1.76
Riau Islands	963	1,179,000	81.68	809	2,309,500	35.03	2.33
Lampung	1887	4,364,300	43.24	2061	8,534,800	24.15	1.79
Maluku	146	900,400	16.22	131	1,787,100	7.33	2.21
North Maluku	137	637,300	21.50	151	1,252,300	12.06	1.78
West Nusa Tenggara	445	2,563,900	17.36	416	5,225,900	7.96	2.18
East Nusa Tenggara	811	2,731,600	29.69	545	5,513,400	9.89	3.00
Papua	291	1,777,700	16.37	229	3,393,100	6.75	2.43
West Papua	205	518,100	39.57	156	986,000	15.82	2.50
Riau	2154	3,553,200	60.62	2016	6,951,200	29.00	2.09
West Sulawesi	182	692,200	26.29	175	1,378,100	12.70	2.07
South Sulawesi	1251	4,348,500	28.77	1066	8,888,800	11.99	2.40
Central Sulawesi	810	1,565,100	51.75	804	3,081,700	26.09	1.98
Southeast Sulawesi	304	1,352,900	22.47	241	2,703,500	8.91	2.52
North Sulawesi	601	1,279,600	46.97	499	2,512,900	19.86	2.37
West Sumatera	1112	2,760,600	40.28	1055	5,545,700	19.02	2.12
South Sumatera	1610	4,358,000	36.94	1543	8,600,800	17.94	2.06
North Sumatera	1578	7,392,700	21.35	1364	14,798,400	9.22	2.32

Number of populations by sex was obtained from the projected number of populations in 2020 which are publicly available from <https://www.bps.go.id/indicator/12/1886/1/jumlah-penduduk-hasil-proyeksi-menurut-provinsi-dan-jenis-kelamin.html>




Figure 2: Heatmaps of weekly incidence rate per 100,000 population (A) and mortality rate per 100,000 population by province (B).

Heterogeneity and factors associated with higher mortality rate at district-level

Table 3. Summary of COVID-19 burden, prevalence of health-related conditions, health care capacity, and socio-economic characteristics associated with higher COVID-19 mortality rate between March 2020 and February 2022 in Indonesia (N=514)

	Mortality rate				
	Quartile 1 N (%)	Quartile 2 N (%)	Quartile 3 N (%)	Quartile 4 N (%)	p value
COVID-19 mortality per 100,000 population					
Quartile 1 (0.28-16.43)					
Quartile 2 (16.43-31.47)					
Quartile 3 (31.47-64.68)					
Quartile 4 (64.68-283.82)					
COVID-19 incidence per 100,000 population					
Quartile 1 (8.13-604.91)	83 (64.34)	35 (27.34)	10 (7.81)	0 (0.00)	0.000
Quartile 2 (604.91-1063.79)	30 (23.26)	52 (40.63)	38 (29.69)	9 (6.98)	
Quartile 3 (1063.79-1964.80)	14 (10.85)	35 (27.34)	52 (40.63)	28 (21.71)	
Quartile 4 (1964.80-10,626.09)	2 (1.55)	6 (4.69)	28 (21.88)	92 (71.32)	
Proportion of ≥60 years old population, %					
Quartile 1 (2.01-7.22)	53 (41.09)	23 (17.97)	31 (24.22)	22 (17.05)	0.000
Quartile 2 (7.22-8.64)	30 (23.26)	49 (38.28)	29 (22.66)	20 (15.50)	
Quartile 3 (8.64-10.43)	27 (20.93)	35 (27.34)	36 (28.13)	30 (23.26)	
Quartile 4 (10.43-20.38)	19 (14.73)	21 (16.41)	32 (25.00)	57 (44.19)	
Prevalence of hypertension, %					
Quartile 1 (9.60-25.70)	47 (36.43)	44 (34.38)	27 (21.09)	12 (9.30)	0.000
Quartile 2 (25.70-30.30)	35 (27.13)	32 (25.00)	35 (27.34)	27 (20.93)	
Quartile 3 (30.30-34.90)	20 (15.50)	34 (26.56)	30 (23.44)	46 (35.66)	
Quartile 4 (34.90-50.00)	27 (20.93)	18 (14.06)	36 (28.13)	44 (34.11)	
Prevalence of diabetes mellitus, %					
Quartile 1 (0.00-1.10)	64 (49.41)	43 (33.59)	19 (14.84)	5 (3.88)	0.000
Quartile 2 (1.10-1.70)	37 (28.68)	36 (28.13)	40 (31.25)	23 (17.83)	
Quartile 3 (1.70-2.50)	20 (15.50)	31 (24.22)	41 (32.03)	39 (30.23)	
Quartile 4 (2.50-50.00)	8 (6.20)	18 (14.06)	28 (21.88)	62 (48.06)	
Prevalence of obesity, %					
Quartile 1 (6.00-25.20)	58 (44.96)	36 (28.13)	25 (19.53)	10 (7.75)	0.000
Quartile 2 (25.20-30.40)	23 (17.83)	38 (29.69)	40 (31.25)	28 (21.71)	
Quartile 3 (30.40-35.10)	27 (20.93)	31 (24.22)	28 (21.88)	42 (32.56)	
Quartile 4 (35.10-50.00)	21 (16.28)	23 (17.97)	35 (27.34)	49 (37.98)	
Prevalence of pneumonia, %					
Quartile 1 (0.20-1.30)	36 (27.91)	34 (26.56)	26 (20.31)	44 (34.11)	0.000
Quartile 2 (1.30-1.80)	31 (24.03)	26 (20.31)	36 (28.13)	42 (32.56)	
Quartile 3 (1.80-2.40)	21 (16.28)	33 (25.78)	39 (30.47)	25 (19.38)	
Quartile 4 (2.40-13.00)	41 (31.78)	35 (27.34)	27 (21.09)	18 (13.95)	
Vaccine coverage for ≥60 years old population, %					
Quartile 1 (0.03-27.61)	55 (42.64)	30 (23.44)	34 (26.56)	10 (7.75)	0.000
Quartile 2 (27.61-36.52)	31 (24.03)	40 (31.25)	35 (27.34)	22 (17.05)	
Quartile 3 (36.52-45.79)	25 (19.38)	37 (28.91)	31 (24.22)	36 (27.91)	
Quartile 4 (45.79-86.20)	18 (13.95)	21 (16.41)	28 (21.88)	61 (47.29)	
Doctor per 100,000 population					
Quartile 1 (0.15-5.43)	34 (28.33)	34 (26.98)	40 (31.75)	17 (13.28)	0.000

Quartile 2 (5.43-7.80)	75 (62.50)	83 (65.87)	71 (56.35)	90 (70.31)	
Quartile 3 (7.80-11.74)	7 (5.83)	7 (5.56)	13 (10.32)	12 (9.38)	
Quartile 4 (11.74-154.25)	4 (3.33)	2 (1.59)	2 (1.59)	9 (7.03)	
Nurse per 100,000 population					
Quartile 1 (0.51-10.59)	27 (22.50)	24 (19.35)	43 (33.59)	31 (24.22)	0.000
Quartile 2 (10.59-17.95)	27 (22.50)	42 (33.87)	29 (22.66)	27 (21.09)	
Quartile 3 (17.95-30.52)	33 (27.50)	32 (25.81)	28 (21.88)	32 (25.00)	
Quartile 4 (30.52-238.28)	33 (27.50)	26 (20.97)	28 (21.88)	38 (29.69)	
Midwife per 100,000 population					
Quartile 1 (0.28-11.46)	45 (36.89)	34 (27.20)	30 (23.44)	16 (12.50)	0.000
Quartile 2 (11.46-18.51)	33 (27.05)	32 (25.60)	32 (25.00)	30 (23.44)	
Quartile 3 (18.51-27.13)	26 (21.31)	31 (24.80)	32 (25.00)	37 (28.91)	
Quartile 4 (27.13-177.41)	18 (14.75)	28 (22.40)	34 (26.56)	45 (35.16)	
Hospital per 100,000 population					
Quartile 1 (0.29-3.90)	38 (36.19)	35 (29.41)	27 (21.77)	19 (14.96)	0.000
Quartile 2 (3.90-7.39)	31 (29.52)	33 (27.73)	34 (27.42)	20 (15.75)	
Quartile 3 (7.39-13.41)	23 (21.90)	34 (28.57)	29 (23.39)	33 (25.98)	
Quartile 4 (13.41-135.21)	13 (12.38)	17 (14.29)	34 (27.42)	55 (43.31)	
Expenditure, millions IDR					
Quartile 1 (3.98-8.51)	73 (56.59)	29 (22.66)	23 (17.97)	4 (3.10)	0.000
Quartile 2 (8.51-10.11)	29 (22.48)	45 (35.16)	36 (28.13)	18 (13.95)	
Quartile 3 (10.11-11.62)	20 (15.50)	39 (30.47)	37 (28.91)	33 (25.58)	
Quartile 4 (11.62-23.58)	7 (5.43)	15 (11.72)	32 (25.00)	74 (57.36)	
Life expectancy, years					
Quartile 1 (55.27-67.24)	61 (47.29)	40 (31.25)	24 (18.75)	5 (3.88)	0.000
Quartile 2 (67.24-69.91)	41 (31.78)	44 (34.38)	35 (27.34)	7 (5.43)	
Quartile 3 (69.91-71.87)	19 (14.73)	31 (24.22)	41 (32.03)	38 (29.46)	
Quartile 4 (71.87-77.65)	8 (6.20)	13 (10.16)	28 (21.88)	79 (61.24)	
Mean length of formal education, years					
Quartile 1 (1.13-7.43)	56 (43.41)	24 (18.75)	29 (22.66)	20 (15.50)	0.000
Quartile 2 (7.43-8.24)	31 (24.03)	40 (31.25)	35 (27.34)	24 (18.60)	
Quartile 3 (8.24-9.28)	28 (21.71)	45 (35.16)	27 (21.09)	27 (20.93)	
Quartile 4 (9.28-12.65)	14 (10.85)	19 (14.84)	37 (28.91)	58 (44.96)	

Table 3 presents the summary of district-level COVID-19 burden, prevalence of health-related conditions, and health care capacity associated with COVID-19 mortality rate across 514 districts in Indonesia. The incidence and mortality rate were highly heterogeneous, ranged from 8.13 to 10,626.09 per 100,000 population, and 0.28 to 283.82 per 100,000 population, respectively. Compared to eastern Indonesia, the mortality rate tends to be higher in the western areas, especially in districts and cities located in Java and Kalimantan Island (Figure 3A). Higher incidence rate was seen in Kalimantan, Sulawesi, and Papua Island (Figure 3B). Based on quartiles, the mortality rates ranged from 0.28 to 16.43 per 100,000 population (quartile 1), 16.43 to 31.47 per 100,000 population (quartile 2), 31.47 to 64.68 per 100,000 population (quartile 3), and 64.68 to 283.82 per 100,000 population (quartile 4). Of 129 districts in the highest mortality rate quartile, 71.32% had the highest incidence rate.




Figure 3: District-level mortality rate (A), and incidence rate (B) in Indonesia between March 2020 and February 2022.

Regarding population health-related conditions, 44.19% of districts with the highest mortality rate had the highest proportion of ≥ 60 years old population (10.43-20.38%), 34.11% had the highest prevalence of hypertension (34.90-50.00%), 48.06% had the highest prevalence of diabetes mellitus (2.50-50.00%), 37.98% had the highest prevalence of obesity (35.10-50.00%), and 13.95% had the highest prevalence of pneumonia (2.40-13.00%). Regarding health care capacity, 47.29% of districts with the highest mortality rate had the highest COVID-19 vaccine coverage for ≥ 60 years old population (45.79-86.20%), 13.28% had the lowest number of doctors per 100,000 population (0.15-5.43), 24.22% had the lowest number of nurses per 100,000 population (0.51-10.59), 12.50% had the lowest number of midwives per 100,000 population (0.28-11.46), and 43.31% had the lowest number of hospitals per 100,000 population (0.29-3.90). Regarding socio-economic, only 3.10% of districts with the highest mortality rate had the lowest expenditure (IDR 3.98-8.51 million), 3.88% had the lowest life expectancy at birth (55.27-67.24 years), and 15.50% had the lowest mean of length of formal education (1.13-7.43 years) (See Table 3 for details).

Table 4. District-level risk factors associated with higher COVID-19 mortality rate between March 2020 and February 2022 in Indonesia

	Bivariable		Multivariable	
	Coefficient (95% CI)	p value	Coefficient (95% CI)	p value
COVID-19 incidence per 100,000 population	0.019 (0.018 to 0.021)	0.000	0.017 (0.015 to 0.019)	0.000
Proportion of ≥ 60 years old population, %	5.703 (4.345 to 7.061)	0.000	2.942 (1.795 to 4.088)	0.000
Prevalence of hypertension, %	2.124 (1.554 to 2.695)	0.000	0.205 (-0.247 to 0.657)	0.373
Prevalence of diabetes mellitus, %	28.152 (24.700 to 31.605)	0.000	12.754 (8.833 to 16.675)	0.000
Prevalence of obesity, %	2.454 (1.916 to 2.992)	0.000	-0.629 (-1.152 to -0.106)	0.019
Prevalence of pneumonia, %	-6.628 (-10.143 to -3.112)	0.000	-0.505 (-3.006 to 1.996)	0.692
Vaccine coverage for ≥ 60 years old population, %	1.288 (1.045 to 1.532)	0.000	-0.013 (-0.253 to 0.226)	0.914
Doctor per 10,000 population	6.989 (3.482 to 10.496)	0.000	-7.046 (-11.145 to -2.947)	0.001
Nurse per 10,000 population	0.900 (-1.094 to 2.894)	0.376	0.088 (-0.146 to 0.323)	0.460
Midwife per 10,000 population	2.337 (-0.036 to 4.711)	0.054	0.132 (-0.057 to 0.321)	0.170
Hospital per 10,000 population	10.332 (7.648 to 13.015)	0.000	1.529 (-1.075 to 4.133)	0.249
Expenditure, thousand IDR	9.946 (8.739 to 11.153)	0.000	0.818 (-0.858 to 2.494)	0.338
Life expectancy, years	7.385 (6.424 to 8.346)	0.000	1.185 (0.086 to 2.283)	0.035
Mean length of formal education, years	11.268 (9.023 to 13.512)	0.000	-2.774 (-5.397 to -0.151)	0.021

Linear regression model was performed based on district-level data from all 514 districts across Indonesia. However, 47 districts were excluded from the final multivariable model, due to missing or unreliable data on either prevalence of hypertension, diabetes mellitus, obesity, or hospital to population ratio.

In bivariable linear regression analysis (Table 4), district-level COVID-19 mortality rate was associated with COVID-19 incidence rate, proportion of ≥ 60 years old individuals, prevalence of hypertension, prevalence of diabetes mellitus, prevalence of obesity, prevalence of pneumonia,

vaccine coverage for ≥ 60 years old population, doctors per population, hospital per population, expenditure, life expectancy, and length of formal education. We found no association between mortality rate with number of nurses and midwives per population. Correlation matrix of COVID-19 burden, prevalence of health-related conditions, vaccine coverage for >60 years old population, health care capacity, and socio-economic characteristics can be seen in Figure 4.

In the multivariable model, higher mortality rate was associated with higher COVID-19 incidence ($p < 0.0001$), higher proportion of ≥ 60 years old population ($p < 0.0001$), higher prevalence of diabetes mellitus ($p < 0.0001$), lower prevalence of obesity ($p = 0.019$), lower number of doctors per population ($p = 0.001$), higher life expectancy at birth ($p = 0.035$), and shorter length of formal education ($p = 0.021$). There was no association between mortality rate with prevalence of hypertension, pneumonia, vaccine coverage for ≥ 60 years old population, number of nurses, midwives, and hospitals per population, and expenditure ($p > 0.05$ each).




Figure 4: Correlation matrix of COVID-19 burden, prevalence of health-related conditions, vaccine coverage for >60 years old population, health care capacity, and socio-economic characteristics. Significance level of the correlation can be seen in Supplementary Table 2.

Discussion

This nationwide ecological study described the epidemiological surveillance data of confirmed COVID-19 cases reported from 514 districts, during three epidemic waves in the first 24 months of the SARS-CoV-2 transmission in Indonesia. The overall case fatality rate was 2.7% (148,034/5,539,333), which equate to a mortality rate of 55 per 100,000 population. The mortality rate was highly heterogeneous and increased over time, with the highest rate seen in East Kalimantan, followed by Yogyakarta, DKI Jakarta, and North Kalimantan. The mortality rate tends to be higher for males than female in the majority of provinces in Indonesia, with the highest male-to-female mortality rate ratio seen in eastern Indonesia provinces. At district-level, higher mortality rate was associated with higher COVID-19 incidence, higher proportion of ≥ 60 years old population, higher prevalence of diabetes mellitus, lower prevalence of obesity, lower number of doctors per population, higher life expectancy at birth, and shorter length of formal education.

Findings from this study revealed the extent of health inequity and its association with COVID-19 mortality across 514 districts in Indonesia. In contrast to a previous province-level analysis (n=34) found the absence of correlation between mortality rate with doctor to population ratio during the first six months of the epidemic [33], our district-level analysis found that a higher COVID-19 mortality rate was strongly associated with a lower number of doctors per 100,000 population at district-level. This finding contrasts a previous finding from a higher-income country, reporting an association between higher COVID-19 mortality rate with higher physicians density in France [34]. In Indonesia, the lack of doctors, combined with the high number of infections [35] and deaths among health care workers and doctors [36], especially during the early phase of the epidemic, had weakened the health system resilience. In the context of a heavily decentralized health system such as in Indonesia [30], coordination and prioritisation of available resources and public health intervention will be critical to ensure optimal health outcomes for vulnerable communities, especially for those areas with lower number of doctors per population. Short-term solutions such as reallocating doctors to districts with the lowest doctor to population ratio may assist local government in mitigating this inequity in health care access. Improving access to medical doctor training for local residents, and providing incentives to doctors in rural areas can provide long-term solution in ensuring future health equity.

Consistent with individual-level risk factors at from diverse settings [18, 25, 37-38], our district-level analysis affirms that higher proportion of elder population (also reflected by higher life expectancy at birth), males gender, and higher prevalence of diabetes mellitus were significantly

associated with higher COVID-19 mortality rate in the general population of Indonesia. This was also consistent with findings from a previous study suggesting that individual-level risk factors such as older age, male sex, and pre-existing hypertension and diabetes were associated with an elevated risk of COVID-19 death during the early epidemic phase in DKI Jakarta, Indonesia [25]. These findings indicate the need of controlling both SARS-Cov-2 transmission and non-communicable diseases, especially in areas with high prevalence of diabetes mellitus. Reducing COVID-19 mortality in such settings may necessitate comprehensive and specific interventions such as improving diagnosis and case management of those known non-communicable diseases, community awareness, as well as a sustainable and accessible social security network that may reduce vulnerability of these communities.

Our analysis reveals the heterogeneity of COVID-19 burden across 34 provinces and 514 districts in Indonesia. The province-level findings suggesting that mortality and incidence rate was higher for males than females, may reflect the cultural phenomenon in Indonesia where males were more likely to get more exposure to the SARS-Cov-2 due to their domestic responsibility to work even during the social restrictions were implemented. Our following findings suggesting higher mortality rate among districts with lower-level of formal education (reflected by shorter mean length of formal education) was consistent with findings from more developed settings such as in the US [11, 39] and Sweden [40]. A lower educational level might be associated with a lower health literacy that can lead to lower access and understanding of public health information. A tailored risk communication and community engagement strategy targeting population living in districts with lower education level is warranted in addressing health inequity in the future.

A previous cohort study in DKI Jakarta reported that higher COVID-9-related mortality risk was significantly associated with lower COVID-19 vaccine coverage at subdistrict-level [24]. By contrast, our current study found that there was no association between district-level COVID-9 mortality rate with COVID-19 vaccine coverage among >60 years old population in Indonesia. This absence of association could possibly be explained by the very low vaccine coverage across the 514 districts. The vaccine coverage was highly varied from 0.03% to 86.20%. The majority of districts (82.3%) still had a vaccine coverage of less than 50% after one year of vaccine roll-out (27 February 2022), thus further highlights the extent of inequity across the country. A previous study from Brazil reported that rapid scaling up of vaccination coverage among elderly Brazilians was associated with significant declines in relative mortality compared with younger individuals, in a setting where the gamma variant predominated [41]. Those findings from DKI Jakarta and Brazil, highlight that rapid vaccination roll outs targeting the most vulnerable is crucial in reducing

COVID-19-related deaths. As per 19 June 2022, the coverage for two-dose and three-doses COVID-19 vaccination in Indonesia was 80.14% (166,911,457/208,265,720 targeted population) and 21.26% (44,273,456/208,265,720), respectively [42].

This study had several limitations. Firstly, this study was based on routine surveillance data derived from district-level health office case reports. The imperfect contact tracing, testing, and reporting activities could result in underreporting of cases, especially those asymptomatic and mild cases, which could cause an overestimation of case fatality rate and an underestimation of mortality rate per population in this study. Secondly, as this study was based on aggregated data available at district level, our analysis was unable to capture and adjust the effect of important individual-level risk factors. Therefore, interpretation of the study findings should be restricted to district-level risk factors. Finally, previous studies in Indonesia have suggested the association between COVID-19 mortality rate with population density [24] and ratio of hospitals bed [33]. However, these variables were not evaluated in our study, due to limited access to the relevant data.

In conclusion, our analysis suggested that COVID-19 disproportionately affected districts with high proportion of elder population, high prevalence of diabetes mellitus, lower doctor to population ratio, higher life expectancy at birth, and lower level of formal education. These findings indicate that vulnerability to death associated with COVID-19 includes not only elders and comorbid, but also males and communities living in area with lower health care capacity and with lower level of education. These findings may inform decisions on health resource allocation against COVID-19 delivering the greatest possible health dividends by prioritising interventions, including even distribution of essential health care need such as doctors, and a tailored risk communication and community engagement for the most vulnerable communities in LMIC, especially with decentralised health systems like in Indonesia. Future nationwide studies incorporating individual and district-level data to assess vulnerability associated with COVID-19-related morbidity and mortality are needed to better comprehend the COVID-19 impact and to better prioritise interventions for the most vulnerable communities.

Acknowledgment

We acknowledge the Ministry of Health of Republic of Indonesia, the National COVID-19 Task Force (Komite Pengendalian COVID-19 dan Pemulihan Ekonomi Nasional), and all health care

workers involved in the care for the COVID-19 patients, as well as those involved in the field data collection.

Contributors

HS was the principal investigator of this study. HS designed the study, did the analysis, and had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. HS, DP, NNA, AIP, AAS, and EP contributed to data collection and verification. LR, DG, and MG supervised the data collection and verification. HS and IRFE drafted the paper. All authors critically revised the manuscript for important intellectual content and all authors gave final approval for the version to be published.

Funding

There was no specific funding for this study. HS, DP, and NNA were supported by funding from UNDP Indonesia. HS, EP, and IRFE were funded by the Wellcome (UK) Africa Asia Programme Vietnam (106680/Z/14/Z).

Conflict of interests

We declare no competing interests.

Data sharing statement

After publication, the datasets used for this study will be made available to others on reasonable requests to the corresponding author, including a detailed research proposal, study objectives and statistical analysis plan.

Acknowledgments

We acknowledge all health care workers involved in the care for the COVID-19 patients, as well as those involved in the field data collection.


References

- [1] World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available: <https://covid19.who.int> [Accessed 19 June 2022].
- [2] Haldane V, Foo CD, Abdalla SM, et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. *Nature Med* 2021; 27:964-980.
- [3] Flor LS, Friedman J, Spencer CN, et al. Quantifying the effects of the COVID-19 pandemic on gender equality on health, social, and economic indicators: a comprehensive review of data from March, 2020, to September, 2021. *Lancet* 2022.


- [4] Barlow P, Schalkwyk MClv, McKee M, et al. COVID-19 and the collapse of global trade: building an effective public health response. *Lancet Planet Heal* 2021; 5:e102-07.
- [5] World Health Organization. Strategic preparedness, readiness and response plan to end the global COVID-19 emergency in 2022. Geneva: World Health Organization; 2022.
- [6] Lowcock EC, Rosella LC, Foisy J, et al. The social determinants of health and pandemic h1n1 2009 influenza severity. *Am J Public Health* 2012;102:51–8.
- [7] Mayoral JM, Alonso J, Garín O, et al. Social factors related to the clinical severity of influenza cases in Spain during the A (H1N1) 2009 virus pandemic. *BMC Public Health* 2013;118:1–7.
- [8] Grantz KH, Rane MS, Salje H, et al. Disparities in influenza mortality and transmission related to sociodemographic factors within Chicago in the pandemic of 1918. *Proc Natl Acad Sci U S A* 2016;113:13839–44.
- [9] Mamelund SE. A socially neutral disease? Individual social class, household wealth and mortality from Spanish influenza in two socially contrasting parishes in Kristiania 1918-19. *Soc Sci Med* 2006;62:923–40.
- [10] Fallah MP, Skrip LA, Gertler S, Yamin D, Galvani AP. Quantifying Poverty as a Driver of Ebola Transmission. *PLoS Negl Trop Dis* 2015;9:1–9.
- [11] Seligman B, Ferranna M, Bloom DE. Social determinants of mortality from COVID-19: A simulation study using NHANES. *PLoS Med* 2021;18:1–13.
- [12] Acharya R, Porwal A. A vulnerability index for the management of and response to the COVID-19 epidemic in India: an ecological study. *Lancet Glob Heal* 2020;8:e1142–51.
- [13] Yoshikawa Y, Kawachi I. Association of Socioeconomic Characteristics with Disparities in COVID-19 Outcomes in Japan. *JAMA Netw Open* 2021;4:1–13.
- [14] Rocha R, Atun R, Massuda A, Rache B, Spinola P, Nunes L, et al. Effect of socioeconomic inequalities and vulnerabilities on health-system preparedness and response to COVID-19 in Brazil: a comprehensive analysis. *Lancet Glob Heal* 2021;9:e782–92.
- [15] Harlem G. Descriptive analysis of social determinant factors in urban communities affected by COVID-19. *J Public Heal (United Kingdom)* 2020;42:466–9.
- [16] Karmakar M, Lantz PM, Tipirneni R. Association of Social and Demographic Factors with COVID-19 Incidence and Death Rates in the US. *JAMA Netw Open* 2021;4:1–12.
- [17] Mena GE, Martinez PP, Mahmud AS, Marquet PA, Buckee CO, Santillana M. Socioeconomic status determines COVID-19 incidence and related mortality in Santiago, Chile. *Science (80-)* 2021;372.
- [18] Oliveira EA, Colosimo EA, Simões e Silva AC, Mak RH, Martelli DB, Silva LR, et al. Clinical characteristics and risk factors for death among hospitalised children and adolescents with COVID-19 in Brazil: an analysis of a nationwide database. *Lancet Child Adolesc Heal* 2021;5:559–68.
- [19] Sousa BLA, Brentani A, Costa Ribeiro CC, Dolhnikoff M, Grisi SJFE, Ferrer APS, et al. Non-communicable diseases, sociodemographic vulnerability and the risk of mortality in hospitalised children and adolescents with COVID-19 in Brazil: a cross-sectional observational study. *BMJ Open* 2021;11:e050724.
- [20] Chen JT, Krieger N. Revealing the unequal burden of COVID-19 by income, race/ethnicity, and household crowding: US county versus zip code analyses. *J Public Heal Manag Pract* 2021;27:S46–56.
- [21] Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* 2020;20:533–4.
- [22] Peta Sebaran COVID-19. <https://covid19.go.id/peta-sebaran> (Accessed 19 June 2022).
- [23] Dyer O. Covid-19: Indonesia becomes Asia's new pandemic epicentre as delta variant spreads. *BMJ* 2021;374:n1815.
- [24] Surendra H, Salama N, Lestari K, Adrian V, Nurhasim A, Shankar AH, et al. Pandemic inequity in a megacity: a multilevel analysis of individual, community, and health care

- vulnerability risks for COVID-19 mortality in Jakarta, Indonesia. *BMJ Glob Heal* 2022;0:e008329.
- [25] Surendra H, Elyazar IRF, Djaafara BA, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. *Lancet Reg Heal - West Pacific* 2021;9:100108.
 - [26] Mboi N, Murty Surbakti I, Trihandini I, et al. On the road to universal health care in Indonesia, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2018;392:581–91.
 - [27] World Health Organization. Noncommunicable Disease (NCD) Country Profile, 2018. Geneva: 2018.
 - [28] Badan Pusat Statistik Indonesia.
<https://www.bps.go.id/dynamictable/2020/02/17/1771/indeks-pembangunan-manusia-menurut-kabupaten-kota-metode-baru-2010-2019.html> 2019.
 - [29] Clark A, Jit M, Warren-Gash C, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. *Lancet Glob Heal* 2020;8:e1003–17.
 - [30] Mahendradhata Y, Trisnantoro L, Listyadewi S, et al. Health Systems in Transition Vol. 7 No. 1 2017. The Republic of Indonesia Health System Review. vol. 7. 2017.
 - [31] Kementerian Kesehatan Republik Indonesia. Indeks Pembangunan Kesehatan Masyarakat.
 - [32] von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008;61:344–9.
 - [33] Wirawan GBS, Januraga PP. Correlation of Demographics, Healthcare Availability, and COVID-19 Outcome: Indonesian Ecological Study. *Front Public Heal* 2021;9:1–8.
 - [34] Tchicaya A, Lorentz N, Leduc K, et al. COVID-19 mortality with regard to healthcare services availability, health risks, and socio-spatial factors at department level in France: A spatial cross-sectional analysis. *PLoS One* 2021;16:1–19.
 - [35] Sinto R, Utomo D, Suwanti, et al. Serum anti-Spike antibody titers before and after heterologous booster with mRNA-1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine. *MedRxiv* 2021.
 - [36] Pramana C, Indriana G, Setyopambudi K. Health Workers and Doctors Death During the Covid-19 Pandemic in Indonesia. *Int J Med Rev Case Reports* 2021;5:1.
 - [37] Harrison SL, Fazio-Eynullayeva E, Lane DA, et al. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. *PLoS Med* 2020;17:1–11.
 - [38] Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. *BMJ* 2020;369:1–12.
 - [39] Hawkins RB, Charles EJ, Mehaffey JH. Socio-economic status and COVID-19-related cases and fatalities. *Public Health* 2020;189:129–34.
 - [40] Calderón-Larrañaga A, Vetrano DL, Rizzuto D, et al. High excess mortality in areas with young and socially vulnerable populations during the COVID-19 outbreak in Stockholm Region, Sweden. *BMJ Glob Heal* 2020;5.
 - [41] Victora PC, Castro PMC, Gurzenda S, et al. Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: analyses of routinely-collected data on vaccine coverage and mortality. *EClinicalMedicine* 2021;38:101036.
 - [42] Vaksinasi COVID-19 Nasional. Available: <https://vaksin.kemkes.go.id/#/vaccines> (Accessed 19 June 2022).


A




A



B



A



B

